In early-stage research, the Moderna messenger RNA-based experimental seasonal flu vaccine developed powerful antibodies against all four strains of influenza virus, according to the vaccine developer.

According to the business, the early-stage study is still ongoing, and a mid-stage study testing the vaccine, mRNA-1010, is now fully enrolled.

Moderna is ahead of other drugmakers, including rival Pfizer, who are also testing their flu vaccine based on messenger RNA, despite the scant evidence.US regulator finds Moderna's Covid-19 vaccine 'highly effective' | Financial Times

Moderna also said that it was working on a pan-respiratory annual booster vaccine that would target a variety of viruses, including COVID-19, influenza, and respiratory syncytial virus.

The new vaccine, mRNA-1345, has shown promising early results, according to the company.

"Around three million people perished each year owing to respiratory illnesses even before the COVID-19 pandemic... our goal is to prevent this suffering with an annual pan-respiratory single-dose booster vaccine," said Chief Executive Officer Stéphane Bancel.